Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.

Role of Insulin Resistance in MAFLD

Open access
Sakurai, Yoshitaka, Kubota, Naoto, Yamauchi, Toshimasa, Kadowaki, Takashi · 2021 · International Journal of Molecular Sciences

Abstract

Many studies have reported that metabolic dysfunction is closely involved in the complex mechanism underlying the development of non-alcoholic fatty liver disease (NAFLD), which has prompted a movement to consider renaming NAFLD as metabolic dysfunction-associated fatty liver disease (MAFLD). Metabolic dysfunction in this context encompasses obesity, type 2 diabetes mellitus, hypertension, dyslipidemia, and metabolic syndrome, with insulin resistance as the common underlying pathophysiology. Imbalance between energy intake and expenditure results in insulin resistance in various tissues and alteration of the gut microbiota, resulting in fat accumulation in the liver. The role of genetics has also been revealed in hepatic fat accumulation and fibrosis. In the process of fat accumulation in the liver, intracellular damage as well as hepatic insulin resistance further potentiates inflammation, fibrosis, and carcinogenesis. Increased lipogenic substrate supply from other tissues, hepatic zonation of Irs1, and other factors, including ER stress, play crucial roles in increased hepatic de novo lipogenesis in MAFLD with hepatic insulin resistance. Herein, we provide an overview of the factors contributing to and the role of systemic and local insulin resistance in the development and progression of MAFLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms22084156

Cites

195 of 195 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Summary of genetic variants related to the pathogenesis of NAFLD. Many genome-wide association studies have identified novel loci associated with disease severity phenotypes of NAFLD. The PNPLA3 (rs738409 C>G) variant, which causes impaired mobilization of TG from lipid droplets, predisposes to progression along the full spectrum of liver damage associated with fatty liver. The TM6SF2 (rs58542926 C>T) variant, a loss-of-function variant, is associated with hepatic steatosis via decreased VLDL-TG secretion in the liver. The MBOAT7 (rs641738 C>T) variant, resulting in lower MBOAT7 protein expression in the liver, is associated with increased hepatic fat content through inducing changes in the remodeling of phospholipids. In addition, other genetic variants known to be involved in the regulation of lipid metabolism (LYPLAL1, APOB, MTP, LPIN1, UCP2), glucose metabolism and lipogenesis (GCKR), innate immunity (IL28B, MERTK), insulin signaling (ENPP1, IRS1), oxidative stress (SOD2), and fibrogenesis (KLF6) have also been reported to be associated with the progression of NAFLD.
Figure 1 Summary of genetic variants related to the pathogenesis of NAFLD. Many genome-wide association studies have identified novel loci associated with disease severity phenotypes of NAFLD. The PNPLA3 (rs738409 C>G) variant, which causes impaired mobilization of TG from lipid droplets, predisposes to progression along the full spectrum of liver damage associated with fatty liver. The TM6SF2 (rs58542926 C>T) variant, a loss-of-function variant, is associated with hepatic steatosis via decreased VLDL-TG secretion in the liver. The MBOAT7 (rs641738 C>T) variant, resulting in lower MBOAT7 protein expression in the liver, is associated with increased hepatic fat content through inducing changes in the remodeling of phospholipids. In addition, other genetic variants known to be involved in the regulation of lipid metabolism (LYPLAL1, APOB, MTP, LPIN1, UCP2), glucose metabolism and lipogenesis (GCKR), innate immunity (IL28B, MERTK), insulin signaling (ENPP1, IRS1), oxidative stress (SOD2), and fibrogenesis (KLF6) have also been reported to be associated with the progression of NAFLD.CC BY · PubMed Central
Figure 2 Summary of factors involved in the pathogenesis of MAFLD. Imbalance between energy intake and expenditure leads to fat accumulation in adipose tissue. When the accumulation exceeds the capacity for adipose tissue remodeling, increased release of FFAs and proinflammatory cytokines with dysregulated production of adipokines results in the development of insulin resistance in the skeletal muscle as well as adipose tissue. Glucose and FFAs not utilized in the skeletal muscle and adipose tissue become substrates for hepatic DNL. Increased uptake of FFAs and relatively decreased VLDL-TG secretion also promote hepatic fat accumulation. Compensatory increase in FFA oxidation is accompanied by enhanced oxidative stress and inflammation. Dysbiosis, defined as an imbalance in the microbiota composition, can disrupt the tight junctions in intestinal endothelial cells, leading to increased mucosal permeability and translocation of bacterial LPS from bacteria. Small intestinal bacterial overgrowth and gut-derived metabolites, such as endogenous ethanol, are also associated with the progression of MAFLD. In addition, people with specific genetic risk variants are also susceptible to the development and progression of MAFLD. Taken together, insulin resistance in adipose tissue and the skeletal muscle, dysbiosis, and genetic predisposition are synergistically involved in fat accumulation and inflammation in the liver, followed by subsequent fibrosis and carcinogenesis, in patients with MAFLD.
Figure 2 Summary of factors involved in the pathogenesis of MAFLD. Imbalance between energy intake and expenditure leads to fat accumulation in adipose tissue. When the accumulation exceeds the capacity for adipose tissue remodeling, increased release of FFAs and proinflammatory cytokines with dysregulated production of adipokines results in the development of insulin resistance in the skeletal muscle as well as adipose tissue. Glucose and FFAs not utilized in the skeletal muscle and adipose tissue become substrates for hepatic DNL. Increased uptake of FFAs and relatively decreased VLDL-TG secretion also promote hepatic fat accumulation. Compensatory increase in FFA oxidation is accompanied by enhanced oxidative stress and inflammation. Dysbiosis, defined as an imbalance in the microbiota composition, can disrupt the tight junctions in intestinal endothelial cells, leading to increased mucosal permeability and translocation of bacterial LPS from bacteria. Small intestinal bacterial overgrowth and gut-derived metabolites, such as endogenous ethanol, are also associated with the progression of MAFLD. In addition, people with specific genetic risk variants are also susceptible to the development and progression of MAFLD. Taken together, insulin resistance in adipose tissue and the skeletal muscle, dysbiosis, and genetic predisposition are synergistically involved in fat accumulation and inflammation in the liver, followed by subsequent fibrosis and carcinogenesis, in patients with MAFLD.CC BY · PubMed Central
Figure 3 After insulin binds to the insulin receptor, autophosphorylation of tyrosine residues in the intracellular subunit of each of the receptors causes docking and phosphorylation of Irs1/Irs2, followed by activation of the downstream kinase cascades, such as the PI3K/Akt pathway. For induction of SREBP1c, mTORC1 activation and concomitant inhibition of FoxO1 via the PI3K/Akt pathway are required. In addition to the DAG-PKCε pathway inhibiting physiological phosphorylation of the insulin receptor, hyperinsulinemia leads to downregulation of hepatic Irs2 expression, resulting in the progression of hepatic insulin resistance. GLUT2 is the major glucose transporter in hepatocytes. In response to an increase in the intracellular glucose concentration, ChREBP induces expression of various genes related to lipogenic enzymes, independent of insulin signaling. Due to elevated Irs1 expression in the perivenous (PV) zone, which is the primary site of lipogenesis, insulin signaling is rather enhanced in the presence of hyperinsulinemia despite the downregulation of Irs2, resulting in increased lipogenesis and development of steatosis. Independent of insulin signaling, ER stress also activates SREBP through increased cleavage of S1P by caspase-2.
Figure 3 After insulin binds to the insulin receptor, autophosphorylation of tyrosine residues in the intracellular subunit of each of the receptors causes docking and phosphorylation of Irs1/Irs2, followed by activation of the downstream kinase cascades, such as the PI3K/Akt pathway. For induction of SREBP1c, mTORC1 activation and concomitant inhibition of FoxO1 via the PI3K/Akt pathway are required. In addition to the DAG-PKCε pathway inhibiting physiological phosphorylation of the insulin receptor, hyperinsulinemia leads to downregulation of hepatic Irs2 expression, resulting in the progression of hepatic insulin resistance. GLUT2 is the major glucose transporter in hepatocytes. In response to an increase in the intracellular glucose concentration, ChREBP induces expression of various genes related to lipogenic enzymes, independent of insulin signaling. Due to elevated Irs1 expression in the perivenous (PV) zone, which is the primary site of lipogenesis, insulin signaling is rather enhanced in the presence of hyperinsulinemia despite the downregulation of Irs2, resulting in increased lipogenesis and development of steatosis. Independent of insulin signaling, ER stress also activates SREBP through increased cleavage of S1P by caspase-2.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 195 references

Cited by

See all 448

Metadata

Authors
Sakurai, Y., Kubota, N., Yamauchi, T., & Kadowaki, T.
Affiliations
  • The University of Tokyo (JP)
  • National Institute of Biomedical Innovation, Health and Nutrition (JP)
  • Toranomon Hospital (JP)
Corresponding author
  • Kubota, Naoto
  • Kadowaki, Takashi
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2021-04-16
Volume
22
Issue
8
Pages
4156
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3155254720
Cited by
448
References
195
Citations by year
2026: 72 · 2025: 129 · 2024: 125 · 2023: 80 · 2022: 37 · 2021: 5
FWCI
9.50
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Japan Society for the Promotion of Science (19K17977)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
non-alcoholic fatty liver disease, insulin resistance, hepatic insulin resistance, hepatic steatosis, liver fibrosis, de novo lipogenesis, gut microbiota, metabolic syndrome, obesity, type 2 diabetes, endoplasmic reticulum stress, liver inflammation, hepatocarcinogenesis
MeSH terms
Animals, Humans, Insulin, Signal Transduction, Metabolic Syndrome, Lipogenesis, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Role of Insulin Resistance in MAFLD. https://app.cochat.ai/papers/10.3390/ijms22084156
The paper
Sakurai, Y., Kubota, N., Yamauchi, T., & Kadowaki, T. (2021). Role of Insulin Resistance in MAFLD. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22084156

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.